Analysis of placental growth factor in placentas of normal pregnant women and women with hypertensive disorders of pregnancy

2006 ◽  
Vol 26 (1) ◽  
pp. 116-119 ◽  
Author(s):  
Shen Hongling ◽  
Li Hongyu ◽  
Chen Hanping ◽  
Guo Yuzhen ◽  
Zhang Ming ◽  
...  
Keyword(s):  
Growth Factor ◽  
Pregnant Women ◽  
Placental Growth Factor ◽  
Hypertensive Disorders Of Pregnancy ◽  
Hypertensive Disorders

Maternal Serum EG-VEGF as A First Trimester Predictor of Hypertensive Disorders of Pregnancy: A Prospective Cohort Study

2021 ◽  
Author(s):  
Shiyu Zeng ◽  
Ling Yu ◽  
Yiling Ding ◽  
Mengyuan Yang
Keyword(s):  
Cohort Study ◽  
Growth Factor ◽  
Prediction Model ◽  
Pregnant Women ◽  
Predictive Value ◽  
Prospective Cohort ◽  
First Trimester ◽  
Hypertensive Disorders Of Pregnancy ◽  
Hypertensive Disorders ◽  
Sensitivity Specificity

Abstract Background This study aims to explore whether plasma endocrine gland-derived vascular endothelial growth factor (EG-VEGF) in the first trimester can be used as a predictor of hypertensive disorders of pregnancy (HDP), and compare it with placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) to evaluate its prediction of HDP value. Methods This is a prospective cohort study that records the medical history of the pregnant women included in the study at 11–13 weeks’ gestation, and analyzes serum biochemical markers including EG-VEGF, PIGF, sFlt-1 and sFlt-1/PIGF. The predictive values of these tests were determined. We used the receiver operating characteristic (ROC) curve to find the optimal cut-off value for each biomarker and compare the operating characteristics (sensitivity, specificity). Logistic regression analysis was used to create a prediction model for HDP based on maternal characteristics and maternal biochemistry. Results Data were obtained from 205 pregnant women. 17 cases were diagnosed with HDP, the incidence rate was 8.2% (17/205). Women who developed HDP had a significantly higher body mass index (BMI) and mean arterial pressure (MAP). Serum EG-VEGF levels in the first trimester are significantly higher in pregnant women with HDP. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value(NPV) of serum EG-VEGF levels more than 227.83 pg/ml for predicting HDP were 43%, 93%, 86% and 62%, respectively. We established a prediction model in the first trimester include maternal BMI, MAP, and EG-VEGF, with an AUC of 0.8861 (95%CI: 0.7905–0.9818), which is better than using EG-VEGF alone (AUC: 0.66). Conclusion This study demonstrated that serum EG-VEGF is a promising biomarker for predicting HDP in the first trimester. It has better predictive performance compared with the currently used biomarkers like PIGF and sFlt-1. Combining maternal clinical characteristics and biochemical tests at 11–13 weeks can effectively identify women at high risk of HDP.

T13.6 Urinary placental growth factor differentiates the hypertensive disorders of pregnancy

2010 ◽  
Vol 1 ◽  
pp. S24-S25
Author(s):  
Neil Campbell ◽  
Robert Ogle ◽  
Annemarie Hennessy ◽  
Charlene Thornton
Keyword(s):  
Growth Factor ◽  
Placental Growth Factor ◽  
Hypertensive Disorders Of Pregnancy ◽  
Hypertensive Disorders

Urinary placental growth factor differentiates the hypertensive disorders of pregnancy

2011 ◽  
Vol 51 (6) ◽  
pp. 523-526 ◽  
Author(s):  
Neil CAMPBELL ◽  
Robert OGLE ◽  
Charlene THORNTON ◽  
Annemarie HENNESSY ◽  
Jason ABBOTT
Keyword(s):  
Growth Factor ◽  
Placental Growth Factor ◽  
Hypertensive Disorders Of Pregnancy ◽  
Hypertensive Disorders

scholarly journals Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy

Hypertension ◽  
2017 ◽  
Vol 70 (6) ◽  
pp. 1228-1237 ◽  
Author(s):  
U. Vivian Ukah ◽  
Jennifer A. Hutcheon ◽  
Beth Payne ◽  
Matthew D. Haslam ◽  
Manu Vatish ◽  
...  
Keyword(s):  
Growth Factor ◽  
Placental Growth Factor ◽  
Hypertensive Disorders Of Pregnancy ◽  
Prognostic Tool ◽  
Hypertensive Disorders

scholarly journals Evaluation of a rapid and simple placental growth factor test in hypertensive disorders of pregnancy

2013 ◽  
Vol 36 (5) ◽  
pp. 457-462 ◽  
Author(s):  
Nóra Gullai ◽  
Balázs Stenczer ◽  
Attila Molvarec ◽  
Gergely Fügedi ◽  
Zoltán Veresh ◽  
...  
Keyword(s):  
Growth Factor ◽  
Placental Growth Factor ◽  
Hypertensive Disorders Of Pregnancy ◽  
Hypertensive Disorders

scholarly journals Urinary placental growth factor as a predictor of complications in hypertensive disorders in pregnancy: a protocol for systematic review and meta-analysis

BMJ Open ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. e046005
Author(s):  
Camille Francoeur ◽  
Julie Moreau ◽  
Samuel Lemaire-Paquette ◽  
Marie-Claude Battista ◽  
Marie-Eve Roy-Lacroix ◽  
...  
Keyword(s):  
Systematic Review ◽  
Growth Factor ◽  
Pregnant Women ◽  
Meta Analysis ◽  
Placental Growth Factor ◽  
Study Quality ◽  
Hypertensive Disorders ◽  
Hypertensive Disorders In Pregnancy ◽  
Study Quality Assessment ◽  
In Pregnancy

IntroductionPreeclampsia is an important cause of maternal and fetal morbidity and mortality. Although the diagnostic and prognostic values of circulating placental growth factor (PlGF) have been extensively studied, urinary PlGF represents an excellent alternative to facilitate sample collection in the follow-up of pregnant women. The aim of this study is to determine whether urinary PlGF levels throughout pregnancy can predict severe maternal, fetal/placental and neonatal complications in women with hypertensive disorders in pregnancy.Methods and analysisStudies that evaluated pregnant women with hypertensive disorders and at least one measurement of urinary PlGF will be included. Studies that measure urinary PlGF after the occurrence of the complications will be excluded. The main outcome will consist of severe maternal complications in women with hypertensive disorders in pregnancy. Secondary outcomes will consist of severe fetal/placental and neonatal complications as defined by the International Collaboration to Harmonize Outcomes for Pre-eclampsia. Prospective cohort studies and case–controls studies reporting original data will be included. Studies will be identified by searching MEDLINE and SCOPUS databases. The first literature search was conducted on 2 March 2020, and another search will be performed before analyses. All eligible studies will be assessed for risk of bias with a standardised 10-items study quality assessment tool adapted from the Study Quality Assessment tools developed by the National Institutes of Health (NIH). Summary of ORs and 95% CIs will be reported to evaluate the association between urinary PlGF levels and hypertensive disorders in pregnancy and its complications. A random-effect meta-analysis will also be performed.Ethics and disseminationReview by an ethics committee will not be required for this systematic review. This study will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and will be submitted for publication in a peer-reviewed journal as well as for presentation at conferences targeting different stakeholders, including researchers, physicians and patients.PROSPERO registration numberCRD42020186313.

Early predictors of placental dysfunction

2016 ◽  
pp. 25-28
Author(s):  
J.M. Melnik ◽  
◽  
A.A. Shlyahtina ◽  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Pregnant Women ◽  
Umbilical Artery ◽  
Placental Growth Factor ◽  
Vascular Endothelial ◽  
Endothelin 1 ◽  
Placental Dysfunction ◽  
Early Predictors ◽  
Endothelial Growth Factor

The article presents the predictors of placental dysfunction on the early stage of pregnancy. The objective: the search for prognostic markers and criteria for the occurrence of placental insufficiency in the early stages of the gestational process to optimize the pregnancy and labor with improved perinatal outcomes. Patients and methods. To solve this goal in the period from 2013 to 2015 were conducted a comprehensive survey of 334 pregnant women, which depending on the peculiarities of pregnancy and childbirth were divided into groups. The control group consisted of 236 pregnant women with uncomplicated gestational period, no morphological signs of placental dysfunction. The study group included 98 patients with a complicated pregnancy who had revealed violations of the fetal-placental relations, which was confirmed by morphological examination of the placenta in the postpartum period. Results. It was found that pregnant women with placental insufficiency in the first trimester of pregnancy have higher levels of interleukin-1B (IL-1v) and interleukin-3 (IL-3) in comparison with physiological pregnancy, as well as there is a direct significant correlation between IL-1v and pulsative index (PI) in the spiral (r=0.84) and uterine artery (r=0.77), and the inverse correlation between the level of IL-3 and PI in the terminal branches of the umbilical artery (r=-0.69). Verified an inverse relationship between the concentration of endothelin-1, the level of vascular endothelial growth factor (r=-0.87) and placental growth factor (r=-0.73), and also a direct link between the content of endothelin-1 and PI in spiral arteries (r=0.89), uterine artery (r=0.83) and the terminal branches of the umbilical artery (r=0.79). Conclusion. Thus, it is proven that early predictors of placental dysfunction can be considered the concentration of endothelin-1, vascular endothelial growth factor, placental growth factor, interleukin-1, interleukin-3, and the indices of pulsative index. Key words: placental dysfunction, predictors, endothelin-1, vascular endothelial growth factor, placental growth factor, interleukin, pulsative index.

Sign in / Sign up

Export Citation Format

Share Document